Macrophage Mitochondrial Switch Boosts Anti-Tumor Immunity
Scientists discover how a mitochondrial protein called NDUFA4 acts as a master switch that controls whether tumor macrophages fight or fuel cancer.
Summary
Researchers at the University of Pennsylvania identified NDUFA4, a subunit of mitochondrial Complex IV, as a critical regulator of tumor-associated macrophage (TAM) function. In tumors, high NDUFA4 expression sustains pro-tumoral macrophages. Interferons reduce NDUFA4 via a conserved bifunctional RNA encoding both NDUFA4L3 and miR-147, shifting TAMs toward an anti-tumor IFN-activated state. This NDUFA4 repression triggers mitochondrial DNA release into the cytoplasm, activating the cGAS-STING pathway and amplifying interferon signaling. The result is increased NK and CD8+ T cell recruitment and stronger anti-tumor immunity. RNA-based therapeutics targeting the Ndufa4 transcript enhanced immune checkpoint blockade efficacy and suppressed B16 melanoma growth in mice, revealing a novel immunotherapeutic strategy.
Detailed Summary
Tumor-associated macrophages (TAMs) are abundant immune cells in the tumor microenvironment that can either promote or suppress cancer progression. A subset called IFN-TAMs—characterized by high expression of CXCL9 and interferon-stimulated genes—correlates with better patient survival and improved responses to immune checkpoint blockade (ICB). However, the molecular mechanisms that drive macrophage programming toward this protective phenotype have remained poorly understood.
This study identifies NDUFA4, a non-catalytic accessory subunit of mitochondrial respiratory Complex IV (cytochrome c oxidase), as a functional switch governing TAM identity. Using mouse tumor models, single-cell transcriptomics, and genetic tools, the researchers demonstrate that NDUFA4 expression is high in pro-tumoral SPP1+ TAMs and low in anti-tumor CXCL9+ IFN-TAMs. Macrophage-specific deletion of NDUFA4 shifted the TAM landscape toward the IFN-TAM state and reduced tumor growth.
Mechanistically, interferons suppress NDUFA4 expression through a conserved bifunctional transcript that co-encodes both NDUFA4L3 (a competitive endogenous RNA-like molecule) and miR-147, a microRNA that directly targets the Ndufa4 3'UTR. This cooperative repression remodels Complex IV, promoting mitochondrial DNA (mtDNA) leakage into the cytoplasm. Cytoplasmic mtDNA activates the cGAS-STING innate sensing pathway, which in turn amplifies the transcriptional IFN response in TAMs—creating a positive feedback loop that sustains and expands the IFN-TAM population. This cascade increases NK cell and CD8+ T cell infiltration, reinforcing anti-tumor adaptive immunity.
To translate these findings therapeutically, the team designed RNA-based therapeutics—including miRNA mimics and antisense oligonucleotides—targeting the Ndufa4 transcript. These agents enhanced ICB (anti-PD-1) efficacy and significantly inhibited B16 melanoma tumor growth in vivo, demonstrating proof-of-concept for mitochondrial reprogramming as an immunotherapy strategy. Human data analyses further supported conservation of this axis in human tumors, with NDUFA4 expression inversely correlating with IFN-TAM signatures and favorable prognosis.
These findings establish mitochondrial Complex IV remodeling as a previously unrecognized mechanism linking cellular metabolism, innate immune sensing, and macrophage functional adaptation in cancer. The identification of a druggable RNA-based circuit (miR-147/NDUFA4L3/NDUFA4) offers a novel therapeutic lever to reprogram TAMs and enhance immunotherapy responses, with potential relevance beyond cancer to other inflammatory and infectious diseases.
Key Findings
- NDUFA4, a Complex IV subunit, sustains pro-tumoral macrophages; its loss shifts TAMs to anti-tumor IFN-activated states.
- Interferons suppress NDUFA4 via a bifunctional transcript co-encoding miR-147 and NDUFA4L3 in a cooperative mechanism.
- NDUFA4 repression causes cytoplasmic mtDNA release, activating cGAS-STING and amplifying IFN transcriptional programs.
- NDUFA4 loss increases NK and CD8+ T cell recruitment, boosting anti-tumor adaptive immunity in mouse models.
- RNA therapeutics targeting Ndufa4 enhanced anti-PD-1 checkpoint blockade efficacy and suppressed B16 melanoma growth.
Methodology
The study combined mouse tumor models (including B16 melanoma), macrophage-specific genetic knockouts, single-cell RNA sequencing, bulk RNA-seq, and human dataset analyses to characterize TAM states. Mechanistic studies included NDUFA4 protein modeling, cytoplasmic mtDNA quantification, and STING pathway assays. RNA-based therapeutics (miRNA mimics and antisense oligonucleotides) were tested in vivo with anti-PD-1 immune checkpoint blockade.
Study Limitations
The primary in vivo evidence relies on mouse tumor models (particularly B16 melanoma), and full validation in human tumor contexts remains needed. The RNA therapeutics tested are early-stage and lack pharmacokinetic and delivery optimization data for clinical translation. The study does not fully resolve whether mtDNA release is the sole mechanism downstream of NDUFA4 loss or whether other metabolic consequences also contribute.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.